Urol. praxi, 2013; 14(4): 160-164

Pharmacotherapy in urology in elderly patients

MUDr.Miroslava Romžová
Urologická klinika Fakultní nemocnice v Hradci Králové

The predominant urologic problems in geriatric patients are symptoms of the lower urinary tract. Most include incontinence, detrusor

instability or benign prostatic hyperplasia. Daily functioning of older patients is affected by these problems, reducing the quality of his

life. Help is often difficult. The solution could be pharmacotherapy. However, due to the use of many drugs to other health problems, there

is a high probability of side effects. Therefore, the need of each patient individually assessed and proceeds very cautiously.

Keywords: geriatric patient, lower urinary tract symptoms, overactive bladder, benign prostatic hyperplasia

Published: October 27, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Romžová M. Pharmacotherapy in urology in elderly patients. Urol. praxi. 2013;14(4):160-164.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Teunissen D, van Weel C, Lagro-Janssen T. Urinary incontinence in older people living in the community: examining help-seeking behaviour. Br J Gen Pract, 2005; 55(519): 776-782.
    2. Teunissen TAM, van Weel C, Lagro-Janssen ALM. Prevalence of urinary-, fecal and double incontinence in the elderly living at home. Int Urogynecol, 1998; 15(1): 10-13. Go to original source... Go to PubMed...
    3. Kellogg J. Parsons Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors, Curr Bladder Dysfunct Rep. 2010; 5(4): 212-218. Go to original source... Go to PubMed...
    4. Romžová M, Hurtová M, Broďák M. Inkontinence moči u stárnoucího pacienta z pohledu urologa. Prakt. lékáren. 2010; 6(5): 227-230.
    5. Krhut J. Hyperaktivní močový měchýř. Jessenius Maxdorf 2007: 149.
    6. Madersbacher M, Awad S, Fall M, Jangknegt RA, Stöhrer M, Weisner B. WHO Statements: Urge inkontinenz beim älteren Menchen - supraspinale Reflexinkontinenz. Urologe B 1998; 38(2): 10. Go to original source...
    7. Smith DA, Chini E, Buntin F. Incontinence in older adults. Adv Nurse Pract 2009; 11(1): 41-44.
    8. Klevetová D, Červinková E. Vyprazdňování je jednou ze základních lidských potřeb, Sestra - příloha Inkontinence 2008.
    9. Krhut J, Mainer K. Inkontinence ve stáří - zvláštnosti diagnostiky a léčby. Urol. praxi 2002; 2: 56-61.
    10. Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RT, Tailor JR. Efficacy of bladder training in older woman with urinary inkontinence. JAMA 1995; 265: 609. Go to original source...
    11. Broďák M, Navrátil P. Inkontinence moči II, základní informace a způsob léčby. PRO. MED. CS, Praha 2006: 32.
    12. Bo K. Pelvic floor muscles exercise for the treatment of stress incontinence: an exercise physiology perspective. Int Urogynecol J 1995; 6: 282. Go to original source...
    13. Krhut J. Inkontinence moče u geriatrických pacientů. Česká geriatrická revue, 2003; 3: 40-47.
    14. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuskarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol, 2005; 48: 5-26. Go to original source... Go to PubMed...
    15. Poršová M, Kolombo I, Porš J, Kobzanová R, Pabišta R. Urgentní mikce a inkontinence a možnosti jejich farmakologické léčby. Urol. praxi, 2008; 9(6): 302-306.
    16. Topinková E. Úskalí farmakoterapie urgentní inkontinence a hyperaktivního močového měchýře. Lékařské listy, 2009; 18: 21-25.
    17. Romžová M, Hurtová M, Pacovský J, Broďák M. Farmakoterapie a její úskalí v léčbě urgentní inkontinence a hyperaktivního močového měchýře. Urol. praxi, 2011; 12(4): 229-233.
    18. Verner P. Porovnání účinnosti a vedlejších účinků anticholinergik při léčbě OAB. Urol. praxi, 2010; 11(5): 241-246.
    19. Drlík P. Nykturie - současné možnosti terapie. Urol. praxi, 2010; 11(4): 176-179.
    20. Liber MM, Rhodes T, Jacobson S, et al. Natural history of benign prostatic enlargement: long-term longitudinal population-based study of prostate volume doubling times. BJU Int 2010; 105: 214-219. Go to original source... Go to PubMed...
    21. Roehrborn CG, Kurth KG, Leriche A, et al. Diagnostic recommendations for clinical practice. In Cockett, ATK et al. The 2nd International Consultation on Benign Prostatic Hyperplasia. Paris, 1993: 271-342.
    22. Hušek P, Pacovský J, Košina J, Broďák M. Léčba BHP v České republice v kontextu doporučených postupů EAU. Urol. praxi, 2012; 13(2): 56-61.
    23. Stárka L, Sosvorová L, Mikšátková P. Herbální přípravky používané při léčbě příznaků benigní hyperplazie prostaty. Urol. praxi, 2012; 13(6): 239-244.
    24. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell - Walsh. Urology 9th ed. Philadelphia: SOUNDERS ELSEVIER, 2007: 2845-2852. ISBN 13: 978-0-8089-2353-4.
    25. Djavan B, Chapple C, Milani S, Marberger M. State of art on the efficacy and tolerability of alpha 1-andrenoreceptor antagonists in patients with lower tract symtoms suggestive of benig prostatic hyperlplasia, Urology 2004; 64: 1081-1088. Go to original source... Go to PubMed...
    26. Gallegos PJ, Frazee LA. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy 2008; 28: 356-365. Go to original source... Go to PubMed...
    27. Yoshida M, Homma Y, Kawabe K. Silodosin, a novel selective alpha 1A-adrenoreceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007; 16: 1955-1965. Go to original source... Go to PubMed...
    28. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N´Dow J, Nordling J, de la Rosettte JJ. Guidelines of the Treatment of Non-neurogenic Male LUTS. European Association of Urology 2011. Go to PubMed...
    29. Hutchinson A, Farmer R, Verhamme K, et al. The efficacy of drugs for the treatment of LUTS/BHP, a study in 6 European countries. Eur Urol 2007; 51(1): 207-215. Go to original source... Go to PubMed...
    30. Roehrborn CG, Marks LS, Center T, et al. Efficacy and safety dutasteride in the four-year treatment of men with benig prostatic hyperplasia. Urology. 2004; 64: 709-715. Go to original source... Go to PubMed...
    31. Klečka J, Hora M, Běhounek P, Eret V, Stránský P. Současné možnosti léčby mikčních symptomů dolních cest močových. Urol. praxi, 2010; 11(3): 124-130.
    32. Pacovský J. Nykturie - jak ji znáte i neznáte. Urol. praxi, 2011; 12(2): 92-96.
    33. Dvořáček J. Kombinovaná léčba benigní hyperplazie prostaty. Urol. praxi, 2012; 13(4): 148-153.
    34. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ. Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology 2013. Go to original source...
    35. Dowling-Castronovo A. Urinary Incontinence Assessment in Older Adults Part I - Transient Urinary Incontinence. Best Practices in Nursing Care to Older Adults, No. 1.1, Revised 2013, http://consultgerirn.org/uploads/File/trythis/try_this_11_1.pdf.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.